{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"051-769-526-971-016","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"051-769-526-971-016"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11714,"type":"PATENT","title":"University of Delaware - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1872,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8367,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* delaware
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 1811
Search Applicants and Owners separately: uni* delaware
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 1811
(b) administering to the patient the HIV integrase inhibitor in an effective amount for intensifying the suppressive antiviral therapy;\n
(c) making one or more post-intensification measurements of the concentration of the episomal artifact in one or more post-intensification samples from the patient; and\n
(d) computing, on at least one processor, the pre-intensification HIV infection success ratio (R) based on the pre-intensification measurement and the one or more post-intensification measurements in accordance with Equations 1-3, 19 and 21:\n\ny.=-(1-(1-ηIIuII)R)ay+ye\nc.=ϕkII(1-ηIIuII)Ray+kIIηIIuIIRay-δc(1)c(t)=c(∞)+(c(0)-c(∞))c-δt+c(∞)δηIIR(1-R)(a(1-(1-ηII)R)-δ)(e-δt-e-a(1-(1-ηII)R)t)(2)c(0)=kIIyeϕRδ(1-R)\nc(∞)=kIIyeR(ϕ+ηII-δηII)δ(1-(1-ηII)R)(3)σ(c)=10-0.21-0.24log10(42×c)(19)mi(ti,k)=max{c(ti,k,ϕ,A,i,ηIIi,Ri)+ei,k,1.2}\nei,k~ℒ\uD835\uDCA9(0,σ2(c)),(21)\n
wherein y is the concentration of actively infected cells in the site of the episomal artifact, c is the concentration of the episomal artifact as measured in the blood, t is the measurement time, a is the death rate of actively infected cells, ye is the rate of production of actively infected cells by processes other than infection, ηII is the ratio-reduction in R following the intensification, uII is a binary variable, which is 1 when the HIV integrase inhibitor is applied and 0 when it is not applied; φ is the ratio of the probability of the episomal artifact formation during an infection event when the HIV integrase inhibitor is not present to the probability of the episomal artifact formation when the HIV integrase inhibitor interrupts an infection event, kII is the probability of the episomal artifact formation when the HIV integrase inhibitor interrupts an infection event, δ is the decay rate of the episomal artifact, mi(ti,k) is the i-th patient's episomal artifact measurement at time ti, k, and ei, k is log-normally distributed zero-mean measurement variance."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein when the pre-intensification HIV infection success ratio (R) in the patient is in the range from 0.95 to 1, the method further comprises quantifying efficient cryptic HIV replication in the patient."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the patient has received the suppressive antiviral therapy for at least 6 months prior to the administration of the HIV integrase inhibitor."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the HIV integrase inhibitor is raltegravir."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the episomal artifact is selected from the group consisting of linear unintegrated HIV DNA, HIV 1-LTR DNA, and HIV 2-LTR circular DNA."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein each of the pre-intensification sample and the one or more post-intensification samples is a whole blood sample."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the intensification lasts for at least 4 weeks."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the one or more post-intensification measurements are made weekly."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the one or more post-intensification measurements are 2 post-intensification measurements."],"number":9,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}